Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel in CIDP
NCT02574962Phase 2Withdrawn
- Start
- Aug 2015
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of repository corticotropin injection in chronic inflammatory demyelinating polyneuropathy (CIDP). Primary endpoint: Number of Participants With Treatment-Related Adverse Events at 28 weeks. Planned start Aug 2015; status: withdrawn.
02
Drugs
repository corticotropin injection
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT02574962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574962.